ERBB2 and neoplasm: Our unpublished observations that T cells from HLA-A2, A3 and A26 patients with pre-existing immunity to HER-2(9369) could also lyse their HER-2/neu+ autologous tumours points to the fact that this peptide is endogenously processed and presented in the surface of tumours by any of the three alleles, thus increasing the population of patients that can be enrolled in peptide-based vaccinations.